依沃西HARMONi-2总生存期阳性（OS HR 0.73、高PD-L1亚组HR 0.58），但数据已于周末官方通稿发布，Summit与康方周一均涨约5%-6%完成定价，盘后无增量反应

Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Published Sept. 14, 2026
Jonathan Gardner
Senior Reporter
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
An illustration of a PD-L1 protein (red) on a cancer cell binding to the immune checkpoint protein PD-1 on a T cell.
Getty Images
Akeso and Summit Therapeutics’ experimental dual-acting cancer drug helped people with lung cancer live about eight months longer than those who got Merck & Co.’s Keytruda in a Phase 3 clinical trial, and showed an even stronger benefit in people whose tumors express high levels of a protein that both medicines target.
The findings could help Akeso and Summit shed doubts about the promise of their drug, called ivonescimab, as well as other experimental therapies that target the proteins “PD-1” and “VEGF” as potential heirs to Keytruda as a backbone of lung cancer care.
Data from “HARMONi-2” have been among the most closely watched in cancer research over the last two years, as the study was the first late-stage trial to show that ivonescimab might be better than Keytruda in helping to significantly
delay disease progression or death
. The latest data cut, evaluating overall survival, also demonstrated a benefit.
Wall Street analysts have raised concerns about the ivonescimab data, questioning whether the China-based trials run by Akeso — its original developer — can translate into a broader global population because of differences in patient characteristics and treatment practices.
The latest findings, released at the World Conference on Lung Cancer meeting in South Korea, could put at least some of those to rest. In the trial population broadly, the relative risk of death when taking ivonescimab was 27% lower than when taking Keytruda. Those who got ivonescimab lived a median 30.8 months, compared with 22.6 months for those who got the Merck immunotherapy.
Results from a smaller group of patients also raised some hopes that ivonescimab will succeed in one of the big Phase 3 trials it will use to support approval in the U.S. and elsewhere. It has already gained
approval in China
.
That trial, titled HARMONi-7, is focused on the group of non-small cell lung cancer patients whose disease expresses high levels of PD-L1, the protein Keytruda latches onto and one of the two ivonescimab does. In that group of patients, the relative risk of death was reduced by 42% among those who got ivonescimab. Importantly, that group of patients is the only one in lung cancer for which Keytruda is typically used as a single agent.
Analysts like TD Cowen’s Tyler Van Buren scored the results as a clear win, writing in a client note that they “not only validate ivonescimab's earlier [progression free survival] benefit, but also strengthen confidence that a PD-1/VEGF bispecific can outperform PD-1 monotherapy on the endpoint that matters most to physicians.”
Meanwhile, Leerink Partners analyst Daina Graybosch remains skeptical. In her own note, she pointed to overall survival numbers in the wider population that fell short of what “Sac-TMT” — an antibody drug conjugate developed by Merck and a Chinese biotechnology company named Kelun —
showed in a similar population
. That drug reduced the relative risk of death by 45%.
Thus, the HARMONI-2 data adds “uncertainty on whether ‘bio-better VEGF/PD-1’ or ‘bio-better chemo’ is more likely to inherit [Keytruda] revenues,” Graybosch wrote.
Recommended Reading
Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda
By
Ben Fidler
•
March 4, 2025
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
Clinical Trials
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Getty Images
Deep Dive
//
State of Play
Protein degraders: chasing undruggable targets
Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.
By Gwendolyn Wu •
Updated July 9, 2025
deliormanli via Getty Images
Emerging biotech
Corporate venture firms stepped in for drug startups during biotech funding pullback
According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.
By Gwendolyn Wu •
Oct. 31, 2025
Keep up with the story. Subscribe to the BioPharma Dive free daily newsletter
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New B…
From Schrödinger, Inc.
September 09, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Allegheny Health Network and The START Center for Cancer Research Announce Strategic Collabora…
From The START Center for Cancer Research
August 25, 2026
Editors' picks
Getty Images
Deep Dive
//
State of Play
Protein degraders: chasing undruggable targets
Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.
By Gwendolyn Wu •
Updated July 9, 2025
deliormanli via Getty Images
Emerging biotech
Corporate venture firms stepped in for drug startups during biotech funding pullback
According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.
By Gwendolyn Wu •
Oct. 31, 2025
Latest in Clinical Trials
AstraZeneca’s newly approved pill fails frontline breast cancer study
By Delilah Alvarado
Tyra disappoints investors with bladder cancer data
By Jonathan Gardner
Novartis RNA drug falls short in rare muscle disease study
By Jacob Bell
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
By Ben Fidler
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell